Ftse Mib
33.494,83
0,60%
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
NASDAQ
19.003,65
0,16%
Bitcoin
98.473,73
0,70%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ SpringWorks Therapeutics Inc (SWTX) SpringWorks Therapeutics Inc (SWTX) Notizie

SpringWorks Therapeutics Inc

SWTX
39,02
2,72 (7,49%)
23 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/11/202415:25GLOBESpringWorks Therapeutics to Participate in the Jefferies..
12/11/202412:34EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202412:33EDGAR2Form 8-K - Current report
12/11/202412:30GLOBESpringWorks Therapeutics Reports Third Quarter 2024..
11/11/202413:00GLOBESpringWorks Therapeutics Announces Mirdametinib Data to be..
11/11/202412:30GLOBESpringWorks Therapeutics Announces Publication of the..
07/11/202412:30GLOBESpringWorks Therapeutics Announces Long-Term Efficacy and..
05/11/202413:00GLOBESpringWorks Therapeutics to Participate in Guggenheim’s..
26/10/202403:46EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
22/10/202413:00GLOBESpringWorks Therapeutics to Report Third Quarter 2024..
03/10/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/9/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/9/202422:09EDGAR2Form 144 - Report of proposed sale of securities
03/9/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202412:30GLOBEFDA Grants Priority Review to SpringWorks Therapeutics’ New..
07/8/202412:36EDGAR2Form 8-K - Current report
07/8/202412:34EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202412:30GLOBESpringWorks Therapeutics Reports Second Quarter 2024..
30/7/202422:01EDGAR2Form 8-K - Current report
29/7/202412:30GLOBESpringWorks Therapeutics Appoints Dr. Martin Mackay to its..
23/7/202413:00GLOBESpringWorks Therapeutics to Report Second Quarter 2024..
02/7/202418:49PRNUSKuehn Law Encourages Investors of SpringWorks, Therapeutics..
01/7/202412:30GLOBESpringWorks Therapeutics Completes Submission of New Drug..
07/6/202422:15EDGAR2Form 8-K - Current report
05/6/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202413:00GLOBESpringWorks Therapeutics to Participate in the Goldman Sachs..
03/6/202422:37EDGAR2Form 144 - Report of proposed sale of securities
23/5/202423:13GLOBESpringWorks Therapeutics Announces Data to be Presented at..
17/5/202422:53EDGAR2Form 8-K - Current report
08/5/202413:00GLOBESpringWorks Therapeutics to Participate in the BofA..
02/5/202412:30GLOBESpringWorks Therapeutics Reports First Quarter 2024..
24/4/202419:31GLOBESpringWorks Therapeutics Announces Abstracts Accepted for..
18/4/202413:00GLOBESpringWorks Therapeutics to Report First Quarter 2024..
04/3/202412:30GLOBESpringWorks Therapeutics Initiates Rolling Submission of New..
01/3/202423:16EDGAR2Form 144 - Report of proposed sale of securities
29/2/202414:30GLOBESpringWorks Therapeutics Announces European Medicines Agency..
27/2/202414:28EDGAR2Form 8-K - Current report
27/2/202414:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/2/202413:29EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202412:51EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202412:44EDGAR2Form 8-K - Current report
27/2/202412:30GLOBESpringWorks Therapeutics Reports Fourth Quarter and Full..
22/2/202413:00GLOBESpringWorks Therapeutics to Present at Upcoming Investor..
21/2/202400:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202419:09EDGAR2Form 144 - Report of proposed sale of securities
14/2/202414:56EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202403:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202403:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:38EDGAR2Form 144 - Report of proposed sale of securities
02/2/202422:01EDGAR2Form 8-K - Current report
Apertura: 36,36 Min: 36,24 Max: 39,61
Chiusura: 36,30

La tua Cronologia

NASDAQ
SWTX
SpringWorks Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network